Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Journal of Orthopaedic TranslationSclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored.
Tao Xiaohui +22 more
doaj +1 more source
Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
Toxins, 2019 Sclerostin is a well-known inhibitor of bone formation that acts on Wnt/β-catenin signaling. This manuscript considers the possible role of sclerostin in vascular calcification, a process that shares many similarities with physiological bone ...
Annelies De Maré +7 more
doaj +1 more source
Increased sclerostin associated with stress fracture of the third metacarpal bone in the Thoroughbred Racehorse [PDF]
, 2018 Objectives: The exact aetiopathogenesis of microdamage induced long bone fractures remains unknown. These fractures are likely the result of inadequate bone remodeling in response to damage.
Henson, F, Hopper, N, Singer, E
core +2 more sources
Coronectomy of deeply impacted lower third molar : incidence of outcomes and complications after one year follow-up [PDF]
, 2015 Objectives: The purpose of present study was to assess the surgical management of impacted third molar with proximity to the inferior alveolar nerve and complications associated with coronectomy in a series of patients undergoing third molar surgery ...
Ajbage, Jimoh Olubanwo +6 more
core +3 more sources
Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling [PDF]
, 2011 Sclerostin is an extracellular negative regulator of bone formation that is a recognized therapeutic target for osteoporosis therapy. In the present study, we performed DNA aptamer selection against sclerostin, then characterized aptamer-sclerostin ...
Chan, C, Leung, CM, Shum, KT, Tanner, JA
core +1 more source
Kidney & Blood Pressure Research, 2018 Background/Aims: Potential relationships between serum sclerostin levels and the levels of bone metabolic markers in maintenance hemodialysis (MHD) patients have yet to be evaluated.
Madoka Sato +4 more
doaj +1 more source
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Phospho1 deficiency transiently modifies bone architecture yet produces consistent modification in osteocyte differentiation and vascular porosity with ageing [PDF]
, 2015 PHOSPHO1 is one of principal proteins involved in initiating bone matrix mineralisation. Recent studies have found that Phospho1 KO mice (Phospho1-R74X) display multiple skeletal abnormalities with spontaneous fractures, bowed long bones, osteomalacia ...
Carriero, A +11 more
core +4 more sources
Novel actions of sclerostin on bone [PDF]
Journal of Molecular Endocrinology, 2019 The discovery that two rare autosomal recessive high bone mass conditions were caused by the loss of sclerostin expression prompted studies into its role in bone homeostasis. In this article, we aim to bring together the wealth of information relating to sclerostin in bone though discussion of rare human disorders in which sclerostin is reduced or ...
Gill, Holdsworth +2 more
openaire +2 more sources
Frontiers in Cell and Developmental Biology, 2020 Sclerostin is an important regulator of bone mass involving Wnt/β-catenin signaling pathway. We aimed to obtain the profile of serum sclerostin level and explore its associations with bone metabolism markers and sex hormones in healthy community-dwelling
Yang Xu +10 more
doaj +1 more source